TScan Therapeutics’ (TCRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a report issued on Wednesday morning,Benzinga reports. The firm currently has a $15.00 target price on the stock.

Several other analysts have also recently commented on TCRX. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a report on Tuesday, November 12th. Wedbush reiterated an “outperform” rating and issued a $7.00 price target (down previously from $10.00) on shares of TScan Therapeutics in a report on Tuesday.

TScan Therapeutics Stock Performance

Shares of NASDAQ:TCRX opened at $2.85 on Wednesday. The business’s fifty day moving average price is $4.82 and its two-hundred day moving average price is $5.87. TScan Therapeutics has a fifty-two week low of $2.60 and a fifty-two week high of $9.69. The stock has a market capitalization of $152.10 million, a price-to-earnings ratio of -2.69 and a beta of 0.79. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.03. The company had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $2.86 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. As a group, analysts predict that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Insider Buying and Selling at TScan Therapeutics

In related news, Director Barbara Klencke bought 5,000 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were purchased at an average price of $5.29 per share, with a total value of $26,450.00. Following the completion of the purchase, the director now owns 45,000 shares of the company’s stock, valued at $238,050. This represents a 12.50 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 2.76% of the company’s stock.

Institutional Investors Weigh In On TScan Therapeutics

A number of hedge funds have recently modified their holdings of TCRX. Great Point Partners LLC acquired a new stake in TScan Therapeutics in the 2nd quarter valued at approximately $5,504,000. Checkpoint Capital L.P. acquired a new stake in TScan Therapeutics in the 3rd quarter valued at approximately $4,110,000. State Street Corp raised its position in TScan Therapeutics by 24.4% in the 3rd quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after buying an additional 148,414 shares during the last quarter. Bank of Montreal Can acquired a new stake in TScan Therapeutics in the 2nd quarter valued at approximately $749,000. Finally, Bank of New York Mellon Corp acquired a new stake in TScan Therapeutics in the 2nd quarter valued at approximately $682,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.